THE BRAINDOOT PLATFORM
Three platforms.
One brain-targeting engine.
Leveraging a global network of partners, our approach enables accelerated timelines and reduced costs to clinical proof ‑ of ‑ concept, while accessing multi‑geography clinical data and regulatory pathways to drive faster approvals.
BLiS™
Brain Linker System
Novel linker platform rationally designs a library of tunable linkers. These linkers are conjugated to therapeutically active molecules to enhance transporter-mediated BBB penetration while retaining their pharmacological activities. Higher CNS penetration and tumor exposure improves therapeutic utility of drugs.
LTiS™
Living Translational Intelligence System
Recapitulates the structural, molecular and functional properties, cellular complexity and transporter regulation of the human blood brain barrier (BBB), enhancing its translational predictability.
The platform evaluates candidates in a human-relevant blood-brain barrier model before they advance into more expensive animal and clinical studies
DRiS™
Discovery and Ranking Intelligence System
DRiS prioritizes drug-linker combinations using molecular properties, transporter interactions, pharmacology, blood-brain barrier characteristics, and physicochemical parameters.
The platform successfully integrates in-vitro, in-silico and in-vivo data to predict drug BBB permeability with high specificity and sensitivity.